VAXXINITY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1166 USD | -3.95% |
|
-75.51% | -86.28% |
| 04-22 | Sector Update: Health Care Stocks Advance Premarket Monday | MT |
| 04-22 | Sector Update: Health Care | MT |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 108M 8.62B |
|---|---|---|---|---|---|
| Net income 2022 | -75M -6B | Net income 2023 | -56M -4.48B | EV / Sales 2022 | - |
| Net cash position 2022 | 72.51M 5.8B | Net cash position 2023 | 15.47M 1.24B | EV / Sales 2023 | - |
| P/E ratio 2022 |
-2.34
x | P/E ratio 2023 |
-1.89
x | Employees | 61 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 43.7% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -3.95% | ||
| 1 week | -75.51% | ||
| Current month | -83.75% | ||
| 1 month | -83.08% | ||
| 3 months | -82.79% | ||
| 6 months | -88.08% | ||
| Current year | -86.28% |
1 week
0.11
0.29
1 month
0.110.74
Current year
0.111.05
1 year
0.113.10
3 years
0.1122.77
5 years
0.1122.77
10 years
0.1122.77
| Managers | Title | Age | Since |
|---|---|---|---|
Mei Mei Hu
FOU | Founder | 41 | 31/12/13 |
Jason Pesile
DFI | Director of Finance/CFO | 50 | 02/01/22 |
Sumita Ray
ADM | Chief Administrative Officer | 50 | 30/09/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 57 | 31/01/23 | |
Peter Diamandis
BRD | Director/Board Member | 62 | 01/02/21 |
George Hornig
BRD | Director/Board Member | 69 | 02/01/22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.1166 | -3.95% | 1,999,747 |
| 25/04/24 | 0.1214 | -8.45% | 2,937,959 |
| 24/04/24 | 0.1326 | -33.70% | 4,946,250 |
| 23/04/24 | 0.2 | -25.82% | 2,114,072 |
| 22/04/24 | 0.2696 | -43.37% | 5,859,924 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Vaxxinity, Inc. is a biotechnology company. The Company is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat common chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its synthetic peptide-based Active Immunotherapy Medicines Platform (AIM Platform, formerly called the Vaxxine Platform) has the potential to enable a new class of medicines. Its pipeline consists of five lead programs focused on chronic disease, particularly neurodegenerative disorders, in addition to other neurology and cardiovascular indications. Its pipeline includes UB-311, UB-312, VXX-301, VXX-401 and UB-313. It also has developed an infectious disease product candidate, UB-612, as a heterologous booster against COVID-19. Its UB-311, which targets the primary pathological process of Alzheimerâs disease (AD) and UB-312, which targets the pathological process of Parkinsonâs disease (PD) and other so-called synucleinopathies.
Calendar
06/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| -86.28% | 14.78M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- VAXX Stock
